



I-012061-O-0001-OT

U.S. Fish & Wildlife Service
Aquatic Animal Drug Approval Partnership Program
Attention: David Erdahl, Ph.D.
AADAP Branch Chief
4050 Bridger Canyon Road
Bozeman, MT 59715

Re: Food-use authorization for lobsters treated with florfenicol

Dear Dr. Erdahl:

You are authorized 750,000 lobsters for human and animal food use. Edible tissues derived from experimental animals treated under the conditions described in this letter may be marketed for human consumption, for use in animal feeds, or released into public waters for possible human consumption. This authorization is in response to your submission dated June 16, 2011. This authorization for the use of AQUAFLO (florfenicol) medicated feed in lobsters is consistent with the public health.

We note that your submission included a request to open this INAD file and a request for a categorical exclusion. Please note that this letter only acknowledges your food use authorization request. Your requests for opening the INAD file and for a categorical exclusion will be addressed under separate cover letters (A-0000, and X-0002). In the future, please make only one request per submission.

FOOD-USE AUTHORIZATION

DRUG IDENTITY/FEED INGREDIENT IDENTITY	AQUAFLO medicated feed (500 g florfenicol/kg premix)
Dosage Form	Medicated feed
SPECIES	Lobsters
Class	Nephropidae and Palinuridae
Number of Animals	750,000
PERMITTED DOSING REGIMEN Maximum Dose (or range)	1) Up to 10 mg florfenicol/kg BW/day 2) Up to 15 mg florfenicol/kg BW/day
Route of Administration	Oral
Frequency and Duration of Dosing	1) 10 mg florfenicol/kg of lobster BW for 10 consecutive days 2) 15 mg florfenicol/kg lobsters BW for 10 consecutive days

MINIMUM INVESTIGATIONAL WITHDRAWAL PERIOD	1) 21 days for lobsters treated with 10 mg florfenicol/kg BW/day 2) 28 days for lobsters treated with 15 mg florfenicol/kg BW/day
MINIMUM INVESTIGATIONAL MILK DISCARD TIME	Not applicable
Other Restrictions OR CONDITIONS	Lobsters that are illegal for harvest during the investigational withdrawal periods can be released immediately after treatment. Euthanized lobsters must not be sent to slaughter or be otherwise available for food.

We will be able to consider a request for a shorter investigational withdrawal period following submission and review of additional human food safety information concerning your product.

The New Animal Drug Regulations, 21 CFR 511.1(b)(4), require the sponsor to submit specific information prior to each shipment or other delivery of the drug for clinical investigation in animals. You may file the notice of the drug shipment electronically to the Center for Veterinary Medicine (CVM) using FDA Form 3458 or FDA's eSubmitter tool. Please refer to the Center's electronic submission information on the CVM website at <http://www.fda.gov/cvm/esubstoc.html>. Alternatively, you can send one copy of the completed form to CVM.

This food-use authorization only applies to the treatment regimen stated above. Any change in the dosage regimen or the combining of this treatment with any other drug will require a separate food-use authorization. Drugs given to control animals must be administered in full compliance with the currently approved use. Your investigators should be made aware of their responsibilities under 21 CFR 511.1(b)(7)(ii) and (c)(1).

Clinical tests conducted under the provisions of this letter do not exempt investigational animals and their products from compliance with any other applicable inspection requirements (see 21 CFR 511.1(b)(5)(iii)).

INVESTIGATIONAL LABELING

You submitted investigational labeling to be included in the file. The appropriate investigational labeling required under 511.1(a) or (b) must be affixed to your investigational drug product before shipping your drug product for studies conducted under 21 CFR 511.1(a) or (b), respectively. Affix the investigational label to each individual drug container.

COUNTING NUMBERS OF LOBSTERS

You should note that this authorization is for a specific number of lobsters. You should begin counting the number of lobsters used from the date you receive our letter starting at zero.

Please provide the total number of lobsters used towards this authorization in your annual reports. We remind you that a lobster treated more than once still only counts as a single lobster toward the authorization.

Additional numbers of lobsters may be requested in the future. A request for additional lobsters should be made with sufficient lead time to allow us to process an amended authorization.

We remind you of the continued necessity to provide annual reports under the FDA/CVM Aquaculture Workload Plan. Your annual report should include: a) a brief summary of the past year's activities and accomplishments in each of the INAD technical sections; b) certification of accountability of all drugs shipped under the INAD, records maintenance for FDA inspection, and compliance with the provisions of 21 CFR Part 511, including notification of adverse effects relative to humans, target animals, or the environment resulting from the use of the investigational drug; c) a list of all investigators, facilities, and species treated; and d) a copy of the current study protocol(s) noting any modification or revision. We recommend that any changes to pivotal study protocols be reviewed by CVM prior to initiating further investigations.

ADDITIONAL COMMENTS

1. In order for us to complete our files, the disposition of all investigational animals and unused drugs must be reported to this office. Please refer to this letter by date and INAD number when reporting the details of clinical investigations or the disposition of investigational animals.
2. Promptly report to this office any adverse reactions that may suggest significant safety hazards.
3. You should obtain a material safety data sheet (MSDS) for the investigational drug and follow the information in the MSDS to protect all individuals who may be exposed to the investigational drug.

If you submit correspondence relating to this letter, you should reference the date and the principal submission identifier found at the top of this letter. If you have any questions or comments, please contact Dr. Cindy Burnsteel Director, Division of Therapeutic Drugs for Food Animals, at 240-276-8341.

Sincerely,

{see appended electronic signature page}

Steven D. Vaughn, DVM
Director
Office of New Animal Drug Evaluation
Center for Veterinary Medicine

**Electronic Signature
Addendum for Submission ID**

I-012061-O-0001-OT

Signing Authority (Role)	Letter Date
Elizabeth Rettie (Office Director) - Acting	9/15/2011

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.